Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11265)
All Articles published online
|
Publishing Process of This Article
|
Jun 25, 2015 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M, Shimizu T, Inoue M, Goto Y, Gotoh H, Inagaki M, Oguchi K. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes 2015; 6(6): 840-849 [PMID: 26131325 DOI: 10.4239/wjd.v6.i6.840] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v6/i6/840.htm |
| Number | Citing Articles |
| 1 |
Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Daisuke Ugamura, Yutaka Koda, Hisaki Shimada, Tetsuya Takasawa, Takahito Ito, Tadahiro Kitamura, Masaki Kobayashi, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito. Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study. Diabetes Therapy 2021; 12(3): 655 doi: 10.1007/s13300-020-00991-y
|
| 2 |
Takahiro Yajima, Kumiko Yajima, Makoto Hayashi, Hiroshi Takahashi, Keigo Yasuda. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring. Diabetes Research and Clinical Practice 2016; 122: 78 doi: 10.1016/j.diabres.2016.10.016
|
| 3 |
Yunfei Song, Jianbo Yang, Wenguang Jing, Qi Wang, Yue Liu, Xianlong Cheng, Fei Ye, Jinying Tian, Feng Wei, Shuangcheng Ma. Systemic elucidation on the potential bioactive compounds and hypoglycemic mechanism of Polygonum multiflorum based on network pharmacology. Chinese Medicine 2020; 15(1) doi: 10.1186/s13020-020-00401-2
|
| 4 |
Shirin Zaresharifi, Mahtab Niroomand, Sarina Borran, Sahar Dadkhahfar. Dermatological side effects of dipeptidyl Peptidase-4 inhibitors in diabetes management: a comprehensive review. Clinical Diabetes and Endocrinology 2024; 10(1) doi: 10.1186/s40842-024-00165-w
|
| 5 |
Tomomi Ishikawa-Tanaka, Michihiro Hosojima, Hideyuki Kabasawa, Ryohei Kaseda, Ryota Yasukawa, Yusuke Yata, Shoji Kuwahara, Emiko Kono, Takuma Takata, Noriaki Iino, Takahiro Tanaka, Nobutaka Kitamura, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita. Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study. Diabetes Therapy 2020; 11(12): 2845 doi: 10.1007/s13300-020-00928-5
|
| 6 |
Rikuma Kitao, Takeshi Fukumoto, Takashi Hashimoto, Kentaro Izumi, Haruki Jimbo, Chihiro Takemori, Chikako Nishigori. Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid showing positive autoantibody responses to multiple epitopes. Journal of Dermatological Science 2021; 103(3): 190 doi: 10.1016/j.jdermsci.2021.08.004
|
| 7 |
Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min, Eun Jung Kyung, Yeo Kyeong Kim, Kwan Woo Lee. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study. Diabetes Therapy 2021; 12(11): 2907 doi: 10.1007/s13300-021-01148-1
|
| 8 |
Daisuke Ugamura, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Yuta Yoshizawa, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita. An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis. Renal Replacement Therapy 2022; 8(1) doi: 10.1186/s41100-022-00409-4
|
| 9 |
Deborah A. Chon, Rachael T. Oxman, Rashmi S. Mullur, Jane Eileen Weinreb. Endocrine Disorders in Kidney Disease. 2019; : 49 doi: 10.1007/978-3-319-97765-2_5
|
| 10 |
Ngoc-Yen T. Pham, Christos Argyropoulos, Nhan Dinh. Diabetes and Kidney Disease. 2022; : 583 doi: 10.1007/978-3-030-86020-2_27
|
| 11 |
Fakhriya Alalawi, Alaaeldin Bashier. Management of diabetes mellitus in dialysis patients: Obstacles and challenges. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2021; 15(3): 1025 doi: 10.1016/j.dsx.2021.05.007
|
| 12 |
Virendra Nath, Manish Ramchandani, Neeraj Kumar, Rohini Agrawal, Vipin Kumar. Computational identification of potential dipeptidyl peptidase (DPP)-IV inhibitors: Structure based virtual screening, molecular dynamics simulation and knowledge based SAR studies. Journal of Molecular Structure 2021; 1224: 129006 doi: 10.1016/j.molstruc.2020.129006
|
| 13 |
Jack Wei Chieh Tan, David Sim, Junya Ako, Wael Almahmeed, Mark E Cooper, Jamshed J Dalal, Chaicharn Deerochanawong, David Wei Chun Huang, Sofian Johar, Upendra Kaul, Sin Gon Kim, Natalie Koh, Alice Pik-Shan Kong, Rungroj Krittayaphong, Bernard Kwok, Bien J Matawaran, Quang Ngoc Nguyen, Loke Meng Ong, Jin Joo Park, Yongde Peng, David KL Quek, Ketut Suastika, Norlela Sukor, Boon Wee Teo, Chee Kiang Teoh, Jian Zhang, Eugenio B Reyes, Su Yen Goh. Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. European Cardiology Review 2021; 16 doi: 10.15420/ecr.2020.52
|
| 14 |
Yukinao Sakai, Saori Sakai, Koji Mugishima, Anna Katayama, Yuichiro Sumi, Yusuke Otsuka, Tomoyuki Otsuka, Shuichi Tsuruoka. Efficacy of Saxagliptin versus Mitiglinid in patients with type 2 diabetes and end-stage renal disease. Renal Replacement Therapy 2017; 3(1) doi: 10.1186/s41100-017-0098-7
|
| 15 |
Rui-Ting Zhang, Yu Liu, Ke-Ke Lin, Wan-Ning Jia, Quan-Ying Wu, Jing Wang, Xiao-Yan Bai. Development of a clinical automatic calculation of hypoglycemia during hemodialysis risk in patients with diabetic nephropathy. Diabetology & Metabolic Syndrome 2023; 15(1) doi: 10.1186/s13098-023-01177-9
|
| 16 |
Byungwook Kim, Dha Woon Im, Heejae Won, Jung Sunwoo, Seung Seok Han, Hajeong Lee, Dong Ki Kim, Kook‐Hwan Oh, Kwon Wook Joo, Yon Su Kim, Joo‐Youn Cho, SeungHwan Lee, Jaeseong Oh, In‐Jin Jang, Yong Chul Kim. Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin. Diabetes, Obesity and Metabolism 2023; 25(6): 1769 doi: 10.1111/dom.15034
|
| 17 |
Maria Concepcion H Gungon, Elaine C Cunanan. Prevalence of Hypoglycemia Among Type 2 Diabetics Undergoing Hemodialysis in a University Hospital. Journal of Medicine, University of Santo Tomas 2020; 4(2): 510 doi: 10.35460/2546-1621.2018-0057
|
| 18 |
Arata Hibi, Yuto Kasahara, Yoshitaka Ishihara, Koichi Hata, Norihisa Hosokawa, Takahiko Nakagawa. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01. CEN Case Reports 2020; 9(3): 189 doi: 10.1007/s13730-020-00452-2
|
| 19 |
Daisuke Kasugai, Kosuke Tajima, Naruhiro Jingushi, Norimichi Uenishi, Akihiko Hirakawa. Multiple limb compartment syndrome as a manifestation of capillary leak syndrome secondary to metformin and dipeptidyl peptidase IV inhibitor overdose. Medicine 2020; 99(29): e21202 doi: 10.1097/MD.0000000000021202
|
| 20 |
K G Lobanova, A S Severina, S A Martinov, M Sh Shamkhalova, M V Shestakova. Glycemic control in patients with diabetes mellitus on hemodialysis. Terapevticheskii arkhiv 2019; 91(10): 124 doi: 10.26442/00403660.2019.10.000352
|
| 21 |
Masanori Abe, Terumi Higuchi, Masari Moriuchi, Masahiro Okamura, Ritsukou Tei, Chinami Nagura, Hiroyuki Takashima, Fumito Kikuchi, Hyoe Tomita, Kazuyoshi Okada. Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. Diabetes Research and Clinical Practice 2016; 116: 244 doi: 10.1016/j.diabres.2016.04.034
|